Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | S100A4 | P26447 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | HBB | P68871 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12646072 | 0.97 | MEN1 (0.52) | MEN1KMT2AS100A4POLBMAPT | |
| SCHEMBL23043831 | 0.90 | MEN1 (0.50) | MEN1KMT2AS100A4POLBMAPT | |
| SCHEMBL22272424 | 0.90 | MEN1 (0.50) | MEN1KMT2AS100A4POLBMAPT | |
| SCHEMBL30273837 | 0.83 | MEN1 (0.50) | MEN1KMT2AS100A4POLBMAPT | |
| SCHEMBL15245116 | 0.82 | MEN1 (0.55) | MEN1KMT2AS100A4POLBMAPT | |
| SCHEMBL12464114 | 0.79 | GSTP1 (0.40) | MEN1KMT2AS100A4POLBTP53 | |
| SCHEMBL13302890 | 0.78 | ALDH1A1 (0.56) | MEN1KMT2APOLBMAPTTP53 | |
| SCHEMBL16975948 | 0.77 | ACHE (0.33) | MEN1KMT2AS100A4POLBACHE | |
| SCHEMBL20924856 | 0.76 | ACHE (0.59) | MEN1KMT2AS100A4POLBMAPT | |
| SCHEMBL8293271 | 0.76 | TSHR (0.48) | MEN1KMT2AS100A4POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649963-A2 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4509184-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3526202-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240368179-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240299366-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-3302572-B3 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240158428-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-05-16 | — | — | US | disclosed |
| US-11964945-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-1002516-A1 | Hair dyes containing indan derivatives | Wella Aktiengesellschaft (DE) | 2000-05-24 | — | — | EP | disclosed |
| US-5994012-A | CHARGE GENERATING COMPOUND, CHARGE TRANSFER COMPOUND AND BINDER | MITA INDUSTRIAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| US-5863688-A | REACTING 1,3-INDANDIONE DERIVATIVE WITH A BROMOACETIC ESTER TO FORM 1,3-INDANDIONE ESTER, ISOMERIZING THE ESTER DERIVATIVE IN PRESENCE OF SODIUM HYDRIDE TO FORM NAPHTHOIC ESTER, OXIDIZING TO FORM NAPHTHOQUINONE DERIVATIVE | MITA INDUSTRIAL CO., LTD (JP) | 1999-01-26 | — | — | US | disclosed |
| EP-0764886-A2 | Naphthoquinone derivative and electrophotosensitive material using the same | MITA INDUSTRIAL CO. LTD. (JP) | 1997-03-26 | — | — | EP | disclosed |
| WO-1995011001-A1 | 1,3-PROPANDIONES FOR DYEING KERATINIC FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1995-04-27 | — | — | WO | disclosed |
| EP-0398258-B1 | INDAN-1,3-DIONE DERIVATIVE AND HERBICIDAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | MITSUBISHI KASEI CORPORATION (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5110342-A | INDAN-1,3-DIONE DERIVATIVE AND HERBICIDAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | MITSUBISHI KASEI CORPORATION (JP) | 1992-05-05 | — | — | US | disclosed |
| US-5076830-A | INDAN-1,3-DIONE DERIVATIVE AND HERBICIDAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | MITSUBISHI KASEI CORPORATION (JP) | 1991-12-31 | — | — | US | disclosed |
| US-4987056-A | IMPROVED SENSITIVITY TO VISIBLE LIGHT | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0398258-A1 | Indan-1,3-dione derivative and herbicidal composition containing the same as active ingredient | MITSUBISHI KASEI CORPORATION (JP) | 1990-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158428-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, ICOSLG | MEN1 2834/4885KMT2A 3760/4885S100A4 2739/4885 |
| US-20240299366-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | MEN1 1077/4885KMT2A 1660/4885S100A4 2728/4885 |
| US-11964945-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | MEN1 1676/4885KMT2A 1478/4885S100A4 4302/4885 |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | MEN1 1674/4885KMT2A 1463/4885S100A4 4293/4885 |
| US-20240368179-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND METHODS OF USE | CRBN, MDM2, UBE2N | MEN1 746/4885KMT2A 1686/4885S100A4 2758/4885 |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | MEN1 1674/4885KMT2A 1463/4885S100A4 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.